Search | Clinical Trials Finder

Conditions: Asthma
Interventions: 10 mg tablet of montelukast (Singulair); Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 7 Years to 35 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions: Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 23
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more

Conditions: HIV Infections
Interventions: Itraconazole; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Rheumatoid Arthritis
Interventions: FLARE Intervention Group; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections
Interventions: MVA/HIV62B vaccine, AIDSVAX B/E vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more

Conditions: Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions: Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss; Drug · Other
Lead sponsor: Chattanooga-Hamilton County Hospital Authority; Other
Eligibility: 1 Year to 21 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: HIV Infections, Opioid-Related Disorders, Pre-Exposure Prophylaxis (PrEP)
Interventions: SIRI Checklist, Enhanced Peer Recovery Coach, SIRI Checklist + Enhanced Peer Recovery Coach; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Breaking Down Barriers; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Allergic Rhinitis
Interventions: ASP-1001 nasal spray, Placebo for ASP-1001; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Days to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis
Interventions: Standard of Care with no acupuncture, Acupuncture; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Peripheral T-Cell Lymphoma
Interventions: KW-0761; Biological
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 2 more

Conditions: Asthma
Interventions: Symbicort pMDI, Budesonide pMDI; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 59
States / cities: Hoover, Alabama • Montgomery, Alabama • Gilbert, Arizona + 56 more

Conditions: Hodgkin Lymphoma, Lymphoma, Large B-Cell, Diffuse, Post-transplant Lymphoproliferative Disorder
Interventions: baltaleucel-T; Biological
Lead sponsor: Cell Medica Ltd; Industry
Eligibility: 12 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Immune Checkpoint Inhibitor-Related Colitis
Interventions: Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper, Placebo Prednisone Capsules, Placebo Vedolizumab, Sulfamethoxazole-Trimethoprim, Placebo for Sulfamethoxazole-Trimethoprim; Drug · Other
Lead sponsor: Shilpa Grover, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Leukemia, Lymphoma
Interventions: aldesleukin, allogeneic natural killer cells, rituximab, cyclophosphamide, fludarabine phosphate; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Non Hodgkin Lymphoma
Interventions: Pembrolizumab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Thymic Carcinoma
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 15
States / cities: Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 11 more

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions: Busulfan, Gemcitabine, Melphalan, Olaparib, Peripheral Blood Stem Cell Transplantation, Pharmacokinetic Study, Rituximab, Vorinostat; Drug · Procedure · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Asthma
Interventions: Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: HIV/AIDS and Infections, Drug Abuse, Adolescent Behavior, Drug Usage
Interventions: S4E, Usual Care; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 14 Years to 21 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Ypsilanti, Michigan

Conditions: Multiple Sclerosis
Interventions: Resilience-Based Program for Support Partners of PwMS; Behavioral
Lead sponsor: Healios Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Flemington, New Jersey

Conditions: Multiple Sclerosis
Interventions: Assessment of leukocyte function.; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis
Interventions: Golimumab; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 9
States / cities: Glendale, Arizona • Aventura, Florida • Palm Harbor, Florida + 6 more

Conditions: Graft Versus Host Disease, Hyperkalemia, Craniectomy, Synostectomy, FOA, Congenital Malformations
Interventions: Irradiated Blood Transfusions, Non-Irradiated Blood Transfusions; Other
Lead sponsor: Valley Anesthesiology Consultants; Other
Eligibility: 2 Months to 6 Months
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Genotype Stratified Pharmacokinetic Study of Montelukast

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents

Study of Itraconazole in Patients With Advanced HIV Infection

Optimizing the Management of Flares in Patients With Rheumatoid Arthritis (RA)

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

SIRI Checklist: An Integrated Hospital Model to Optimize HIV Prevention in Persons Who Inject Drugs

Breaking Down Barriers to Diabetes Self-Care

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

A Study to Analyze the Effect of Acupuncture on Mobility And Quality of Life in Multiple Sclerosis

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

VENTURI (VENTilation Using Respiratory Imaging)

Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention

Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis

Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)

Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair